266 related articles for article (PubMed ID: 3485463)
1. The mechanism of action of MPTP and MPP+ on endogenous dopamine release from the rat corpus striatum superfused in vitro.
Chang GD; Ramirez VD
Brain Res; 1986 Mar; 368(1):134-40. PubMed ID: 3485463
[TBL] [Abstract][Full Text] [Related]
2. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
Sirinathsinghji DJ; Heavens RP; McBride CS
Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784
[TBL] [Abstract][Full Text] [Related]
3. Effects on dopamine metabolism of MPTP and MPP+ infused through a push-pull cannula into the caudate nucleus of awake adult male rats.
Chang GD; Ramirez VD
Brain Res; 1987 Oct; 424(1):49-57. PubMed ID: 3319041
[TBL] [Abstract][Full Text] [Related]
4. Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites.
Johannessen JN; Sobotka TJ; Weise VK; Markey SP
J Neurochem; 1991 Sep; 57(3):981-90. PubMed ID: 1677682
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of 1-methyl-4-phenylpyridinium ion (MPP+) on dopamine and serotonin metabolism in rat striatum as assayed in vivo by a micro-dialysis technique.
Ozaki N; Nakahara D; Kaneda N; Kiuchi K; Okada T; Kasahara Y; Nagatsu T
J Neural Transm; 1987; 70(3-4):241-50. PubMed ID: 3500274
[TBL] [Abstract][Full Text] [Related]
6. Failure to detect 6-hydroxydopamine in rat striatum after the dopamine releasing drugs dexamphetamine, methylamphetamine and MPTP.
Rollema H; De Vries JB; Westerink BH; Van Putten FM; Horn AS
Eur J Pharmacol; 1986 Dec; 132(1):65-9. PubMed ID: 3102260
[TBL] [Abstract][Full Text] [Related]
7. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity.
Kinemuchi H; Arai Y; Toyoshima Y
Neurosci Lett; 1985 Jul; 58(2):195-200. PubMed ID: 3876524
[TBL] [Abstract][Full Text] [Related]
8. MPP+-induced increases in extracellular potassium ion activity in rat striatal slices suggest that consequences of MPP+ neurotoxicity are spread beyond dopaminergic terminals.
Hollinden GE; Sanchez-Ramos JR; Sick TJ; Rosenthal M
Brain Res; 1988 Dec; 475(2):283-90. PubMed ID: 3265070
[TBL] [Abstract][Full Text] [Related]
9. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
Bradbury AJ; Costall B; Domeney AM; Testa B; Jenner PG; Marsden CD; Naylor RJ
Neurosci Lett; 1985 Oct; 61(1-2):121-6. PubMed ID: 2417166
[TBL] [Abstract][Full Text] [Related]
10. Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse.
Perry TL; Yong VW; Jones K; Wall RA; Clavier RM; Foulks JG; Wright JM
Neurosci Lett; 1985 Aug; 58(3):321-6. PubMed ID: 3876525
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and biochemical changes following acute administration of MPTP and MPP+.
Tadano T; Satoh N; Sakuma I; Matsumura T; Kisara K; Arai Y; Kinemuchi H
Life Sci; 1987 Mar; 40(13):1309-18. PubMed ID: 2436017
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the tyrosine hydroxylase system by MPTP, 1-methyl-4-phenylpyridinium ion (MPP+) and the structurally related compounds in vitro and in vivo.
Nagatsu T; Hirata Y
Eur Neurol; 1987; 26 Suppl 1():11-5. PubMed ID: 2884110
[TBL] [Abstract][Full Text] [Related]
13. Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport.
Mayer RA; Kindt MV; Heikkila RE
J Neurochem; 1986 Oct; 47(4):1073-9. PubMed ID: 3489072
[TBL] [Abstract][Full Text] [Related]
14. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium.
Vyas I; Heikkila RE; Nicklas WJ
J Neurochem; 1986 May; 46(5):1501-7. PubMed ID: 3485701
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of L-deprenyl on MPP+- and MPTP-induced dopamine overflow in microdialysates of striatum and nucleus accumbens.
Wu WR; Zhu ZT; Zhu XZ
Life Sci; 2000 Jun; 67(3):241-50. PubMed ID: 10983868
[TBL] [Abstract][Full Text] [Related]
16. Mesencephalic dopamine neurons become less sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity during development in vitro.
Danias P; Nicklas WJ; Ofori S; Shen J; Mytilineou C
J Neurochem; 1989 Oct; 53(4):1149-55. PubMed ID: 2788714
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tyrosine hydroxylation in rat striatal tissue slices by 1-methyl-4-phenylpyridinium ion.
Hirata Y; Nagatsu T
Neurosci Lett; 1985 Jun; 57(3):301-5. PubMed ID: 3929190
[TBL] [Abstract][Full Text] [Related]
18. Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat.
Desole MS; Esposito G; Fresu L; Migheli R; Enrico P; Miele M; De Natale G; Miele E
Neurosci Lett; 1993 Oct; 161(2):121-3. PubMed ID: 7903798
[TBL] [Abstract][Full Text] [Related]
19. 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity.
Irwin I; Langston JW; DeLanney LE
Life Sci; 1987 Feb; 40(8):731-40. PubMed ID: 3492652
[TBL] [Abstract][Full Text] [Related]
20. Striatal and urinary DOPAC/DA ratio may indicate a long-lasting DA release enhancement by MPP+ and MPTP.
Bagchi SP
Neurochem Res; 1998 Feb; 23(2):127-34. PubMed ID: 9475505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
